NASDAQ:PMN ProMIS Neurosciences (PMN) Stock Price, News & Analysis $1.09 -0.02 (-1.80%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About ProMIS Neurosciences Stock (NASDAQ:PMN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ProMIS Neurosciences alerts:Sign Up Key Stats Today's Range$1.09▼$1.1750-Day Range$1.09▼$1.6652-Week Range$0.95▼$3.10Volume51,510 shsAverage Volume71,672 shsMarket Capitalization$20.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Read More… Who are Nvidia’s New Silent Partners? (Ad)Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.I call these Nvidia’s “Silent Partners.” ProMIS Neurosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks14th Percentile Overall ScorePMN MarketRank™: ProMIS Neurosciences scored higher than 14% of companies evaluated by MarketBeat, and ranked 938th out of 1,000 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ProMIS Neurosciences.Read more about ProMIS Neurosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ProMIS Neurosciences are expected to grow in the coming year, from ($0.24) to ($0.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProMIS Neurosciences is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProMIS Neurosciences is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProMIS Neurosciences has a P/B Ratio of 5.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ProMIS Neurosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.63% of the float of ProMIS Neurosciences has been sold short.Short Interest Ratio / Days to CoverProMIS Neurosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProMIS Neurosciences has recently increased by 12.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProMIS Neurosciences does not currently pay a dividend.Dividend GrowthProMIS Neurosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.63% of the float of ProMIS Neurosciences has been sold short.Short Interest Ratio / Days to CoverProMIS Neurosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProMIS Neurosciences has recently increased by 12.89%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for ProMIS Neurosciences this week, compared to 0 articles on an average week.Search Interest5 people have searched for PMN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, ProMIS Neurosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $177,100.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.39% of the stock of ProMIS Neurosciences is held by insiders.Percentage Held by Institutions50.13% of the stock of ProMIS Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ProMIS Neurosciences' insider trading history. Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PMN Stock News HeadlinesProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster Buys 60,000 SharesSeptember 25, 2024 | insidertrades.comProMIS Neurosciences (NASDAQ:PMN) Stock, Insider Trading ActivityOctober 5 at 1:20 AM | benzinga.com⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.October 5, 2024 | Behind the Markets (Ad)ProMIS Neurosciences (NASDAQ:PMN) Stock, Short Interest ReportOctober 5 at 1:20 AM | benzinga.comProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster Acquires 60,000 Shares of StockSeptember 25, 2024 | americanbankingnews.comProMIS Neurosciences Inc PMNSeptember 19, 2024 | morningstar.comProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral NeurosciencesSeptember 12, 2024 | globenewswire.comProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comSee More Headlines PMN Stock Analysis - Frequently Asked Questions How have PMN shares performed this year? ProMIS Neurosciences' stock was trading at $1.15 at the beginning of the year. Since then, PMN shares have decreased by 5.2% and is now trading at $1.09. View the best growth stocks for 2024 here. How were ProMIS Neurosciences' earnings last quarter? ProMIS Neurosciences, Inc. (NASDAQ:PMN) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. How do I buy shares of ProMIS Neurosciences? Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/08/2024Today10/04/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PMN CUSIPN/A CIK1374339 Webwww.promisneurosciences.com Phone(416) 847-6898FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-587.38% Return on Assets-133.87% Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.44 Sales & Book Value Annual Sales$10,000.00 Price / Sales2,066.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book5.45Miscellaneous Outstanding Shares18,961,000Free Float17,749,000Market Cap$20.67 million OptionableNot Optionable Beta0.61 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:PMN) was last updated on 10/5/2024 by MarketBeat.com Staff From Our PartnersThe panic button has already been pressedIf you missed it, my emergency election broadcast is now available on replay.Porter & Company | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed ...InvestorPlace | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMIS Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.